Actively Recruiting
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
Led by REGENXBIO Inc. · Updated on 2025-11-25
200
Participants Needed
1
Research Sites
193 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
CONDITIONS
Official Title
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male participants aged 0 to under 25 years
- Diagnosed with Duchenne muscular dystrophy
- Signed and dated informed consent form and assent as required by local rules
You will not qualify if you...
- Previous participation in a gene therapy trial or receipt of a gene therapy drug
- Other inclusion or exclusion criteria as applicable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rare Disease Research
Atlanta, Georgia, United States, 30329
Actively Recruiting
Research Team
P
Patient Advocacy
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here